StockNews.com upgraded shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Get Rating) from a buy rating to a strong-buy rating in a report released on Friday. Vanda Pharmaceuticals Stock Performance NASDAQ VNDA opened at $6.50 on Friday. The firm has a market capitalization of $373.39 million, a PE ratio of 22.41 and a beta of 0.68. The […]
Vanda Pharmaceuticals (NASDAQ:VNDA – Get Rating) will issue its quarterly earnings data after the market closes on Wednesday, May 3rd. Parties that wish to register for the company’s conference call can do so using this link. Vanda Pharmaceuticals (NASDAQ:VNDA – Get Rating) last announced its quarterly earnings results on Wednesday, February 8th. The biopharmaceutical company […]
KBC Group NV lessened its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Rating) by 49.6% during the 2nd quarter, Holdings Channel reports. The firm owned 5,483 shares of the biopharmaceutical company’s stock after selling 5,389 shares during the period. KBC Group NV’s holdings in Vanda Pharmaceuticals were worth $60,000 as of its […]